Nuveen Asset Management LLC Acquires 326,636 Shares of Biohaven Ltd. (NYSE:BHVN)

Nuveen Asset Management LLC increased its stake in shares of Biohaven Ltd. (NYSE:BHVN - Free Report) by 55.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 919,235 shares of the company's stock after buying an additional 326,636 shares during the quarter. Nuveen Asset Management LLC owned 0.91% of Biohaven worth $34,333,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Spire Wealth Management bought a new position in shares of Biohaven during the 4th quarter worth approximately $56,000. Amalgamated Bank increased its position in shares of Biohaven by 21.9% during the fourth quarter. Amalgamated Bank now owns 2,929 shares of the company's stock valued at $109,000 after acquiring an additional 527 shares during the last quarter. US Bancorp DE increased its position in shares of Biohaven by 36.7% during the fourth quarter. US Bancorp DE now owns 2,971 shares of the company's stock valued at $111,000 after acquiring an additional 798 shares during the last quarter. Quarry LP bought a new stake in Biohaven during the fourth quarter worth $112,000. Finally, Lazard Asset Management LLC boosted its position in Biohaven by 47.4% in the fourth quarter. Lazard Asset Management LLC now owns 3,207 shares of the company's stock worth $119,000 after purchasing an additional 1,031 shares during the last quarter. Institutional investors own 88.78% of the company's stock.

Insider Activity

In other Biohaven news, Director John W. Childs bought 32,700 shares of Biohaven stock in a transaction that occurred on Tuesday, March 4th. The stock was acquired at an average cost of $30.47 per share, for a total transaction of $996,369.00. Following the completion of the transaction, the director now directly owns 2,320,571 shares in the company, valued at $70,707,798.37. This represents a 1.43% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. 16.00% of the stock is owned by company insiders.

Biohaven Trading Up 1.5%

Shares of BHVN stock traded up $0.24 during trading on Monday, reaching $15.67. 2,283,708 shares of the company's stock traded hands, compared to its average volume of 1,238,104. The firm's 50-day moving average is $20.97 and its 200 day moving average is $32.83. The company has a market capitalization of $1.60 billion, a P/E ratio of -1.68 and a beta of 1.18. Biohaven Ltd. has a 1 year low of $14.69 and a 1 year high of $55.70.

Biohaven (NYSE:BHVN - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($2.17) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.67) by ($0.50). As a group, sell-side analysts predict that Biohaven Ltd. will post -8.9 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on BHVN shares. Robert W. Baird decreased their target price on Biohaven from $60.00 to $57.00 and set an "outperform" rating for the company in a research report on Monday, April 28th. HC Wainwright restated a "buy" rating and set a $54.00 price target on shares of Biohaven in a research report on Tuesday, March 4th. Deutsche Bank Aktiengesellschaft set a $60.00 price objective on shares of Biohaven and gave the stock a "buy" rating in a report on Thursday, March 20th. William Blair upgraded shares of Biohaven to a "strong-buy" rating in a research note on Thursday, April 24th. Finally, JPMorgan Chase & Co. reduced their target price on shares of Biohaven from $72.00 to $68.00 and set an "overweight" rating for the company in a research report on Wednesday, March 5th. One equities research analyst has rated the stock with a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, Biohaven has a consensus rating of "Buy" and a consensus price target of $59.46.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.